Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, 507 Zhengmin Road, Shanghai, 200433, China.
Foundation Programme, University Hospitals of Derby and Burton NHS Trust, Derby, UK.
Gen Thorac Cardiovasc Surg. 2021 Sep;69(9):1291-1302. doi: 10.1007/s11748-021-01626-0. Epub 2021 Apr 25.
Uniportal (U-VATS) pneumonectomy in lung cancer patients remains disputed in terms of oncological outcomes, and has not been compared to open approaches previously. We evaluated U-VATS versus open pneumonectomy at a high-volume centre.
Patients undergoing pneumonectomy for lung cancer between 2014 and 2018 were retrospectively reviewed and divided into two groups based on surgical approach. Propensity-score matching was performed (1:1), and intention-to-treat analysis applied. Overall survival, operative time, intraoperative blood loss, hospital-stay and readmission, pain, time to adjuvant therapy, morbidity and mortality were tested. Statistical analysis was performed using SAS version 9.4 (SAS Institute Inc. NC) RESULTS: 341 patients underwent pneumonectomy; 23 patients with small-cell lung cancer were excluded, thus 318 patients were submitted to surgery by either U-VATS (n = 54) or open (n = 264). After matching, 52 patients were selected from each group. Five patients (9.2%) in the uniportal group required conversion. There was no significant difference in intraoperative outcomes, complication rates, readmission rates or mortality. The U-VATS group experienced significantly shorter hospital stay (mean ± SD; 6.7 ± 2.7 vs 9.1 ± 2.3 days, p < 0.001) and reported less pain postoperatively (p < 0.0001). Adjuvant chemotherapy was initiated sooner after U-VATS (38.1 ± 8.4 vs 50.8 ± 11.5 days, p < 0.0001). Overall survival appeared to be superior in U-VATS when pathology stage was aligned (p = 0.001).
Uniportal VATS is a safe and effective alternative approach to open surgery for pneumonectomy in lung cancer. Complications and oncologic outcomes were comparatively similar. U-VATS showed lower postoperative pain, shorter hospital stay and superior overall survival. The study is a preliminary analysis.
单孔(U-VATS)肺癌患者的全肺切除术在肿瘤学结果方面仍存在争议,并且以前尚未与开放方法进行比较。我们在一个高容量中心评估了 U-VATS 与开放全肺切除术。
回顾性分析了 2014 年至 2018 年间因肺癌行全肺切除术的患者,并根据手术方式分为两组。进行了倾向评分匹配(1:1),并进行了意向治疗分析。测试了总生存率、手术时间、术中出血量、住院时间和再入院、疼痛、辅助治疗时间、发病率和死亡率。使用 SAS 版本 9.4(SAS Institute Inc. NC)进行统计分析。
341 例患者行全肺切除术;排除 23 例小细胞肺癌患者,因此 318 例患者接受 U-VATS(n=54)或开放(n=264)手术。匹配后,每组各选择 52 例患者。单孔组有 5 例(9.2%)患者需要中转。术中结果、并发症发生率、再入院率或死亡率无显著差异。U-VATS 组的住院时间明显更短(平均值±标准差;6.7±2.7 与 9.1±2.3 天,p<0.001),术后疼痛明显较轻(p<0.0001)。U-VATS 后辅助化疗启动时间更早(38.1±8.4 与 50.8±11.5 天,p<0.0001)。当病理分期一致时,U-VATS 的总生存率似乎更高(p=0.001)。
单孔 VATS 是肺癌全肺切除术的一种安全有效的开放手术替代方法。并发症和肿瘤学结果比较相似。U-VATS 术后疼痛较轻、住院时间较短、总生存率较高。本研究为初步分析。